Search

AN UNBIASED ANALYSIS OF THE RESEARCH ON THE CURRENT COVID VACCINES

As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States. (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days)


The Centers for Disease Control and Prevention said in its Morbidity and Mortality Weekly Report that 0.03%, or 1,266, of the more than 4 million people who have received the first dose of Moderna's COVID-19 vaccine experienced adverse events. Of the recipients with side effects, 108 were identified for further review as severe allergic reactions, including anaphylaxis – a life-threatening allergic reaction that the CDC says can occur after a vaccination, although rarely. It typically occurs within minutes to hours.


LESS THAN 1% OF PEOPLE who have received Moderna's coronavirus vaccine have experienced adverse side effects.


Among the 108 instances of allergic reaction, 10 were determined to be anaphylaxis, amounting to a rate of 2.5 anaphylaxis cases per 1 million vaccine doses administered. Of the 10, it included nine people who had a previous history of anaphylaxis. Follow-up information was available for eight people, all of whom had recovered from their reactions and been sent home. Of the remaining people who experienced adverse side effects, 47 were determined to be non-anaphylaxis allergic reactions, another 47 were considered to be non-allergic adverse events and four cases were undetermined.


The two-dose COVID-19 vaccine developed by Moderna received emergency use authorization in the U.S. in December and has been deemed 94.1% effective in preventing COVID-19, which has infected more than 24.6 million people in the country and killed more than 411,400.


An earlier analysis of the incidence rate of anaphylaxis after receiving the first dose of the coronavirus vaccine developed by Pfizer and BioNTech revealed it was at a rate of 11.1 cases per 1 million doses.


The CDC and FDA identified reports of suspected anaphylaxis in VAERS, the national passive surveillance (i.e., spontaneous reporting) system for monitoring adverse events after immunization. CDC physicians screened VAERS reports describing suspected severe allergic reactions and anaphylaxis and applied Brighton Collaboration case definition criteria for anaphylaxis*. After initial screening, reports with sufficient evidence to suggest anaphylaxis were followed up by collecting information from medical records and through direct outreach to health care facilities and treating health care providers, and, in some cases, vaccine recipients. Physician reviewers classified all initially identified case reports as anaphylaxis or not anaphylaxis and used clinical judgment to further categorize reports that were considered not anaphylaxis as nonanaphylaxis allergic reactions or nonallergic adverse events.


Nonallergic adverse events, mostly vasovagal (e.g., fainting or the sensation of fainting) or suspected anxiety-related, were excluded from the final analyses. Anaphylaxis and nonanaphylaxis allergic reaction cases with symptom onset occurring later than the day after vaccination (i.e., outside the 0–1-day risk window) were also excluded because of the difficulty in clearly attributing allergic reactions with onset later than this to vaccination.


In nine of 10 cases of anaphylaxis after receipt of Moderna COVID-19 vaccine, patients had symptom onset within 30 minutes of vaccination, and nine anaphylaxis patients also had a history of allergies or allergic reactions, including some with previous anaphylaxis events; up to 30% of persons in the general population might have some type of allergy or history of allergic reactions.


The clinical and epidemiologic characteristics of anaphylaxis case reports after receipt of Moderna COVID-19 vaccine are similar to those reported after receipt of the Pfizer-BioNTech COVID-19 vaccine. For both vaccines, symptom onset after vaccination occurred quickly, usually within minutes. A strong female predominance of anaphylaxis case reports exists for both vaccines. Finally, many persons experiencing anaphylaxis after receiving either vaccine had a history of allergies or allergic reactions, with several having experienced an anaphylaxis episode in the past. Similar patient characteristics in case reports of nonanaphylaxis allergic reactions were observed among the two vaccines.

FACT: We have COVID-19 vaccines available now because science and health experts responded swiftly to a deadly public health crisis

Myths and fears: Many people have voiced concerns about how quickly the vaccines have become available, how short the testing process was, or how political the whole vaccine production effort has gotten because of the national election.

There are claims that it was rushed, or that “corners were cut” in the clinical trials or the government’s safety review and approval process.


The bottom line: The entire process went faster than usual for explainable reasons, but still followed the usual steps for testing and review. The most important reasons for speed: modern scientific tools are faster than old ones, and there was a worldwide effort to reduce or remove the usual barriers and delays in vaccine research, production and distribution. A large number of ordinary people volunteered for clinical trials of the vaccines, which meant we got the answers to key questions about safety and protection quickly.


The vaccines still received independent review and approval, under emergency rules put in place before this pandemic for situations where the public’s health is at serious and immediate risk, as it is now.


The effort started with rapid research on the genetics of the coronavirus, starting in January. Scientific tools have made it possible to “read” the genetic material of a virus in mere days, where it once took months. Meanwhile, scientists and vaccine makers had already been working for years to develop a “platform” approach to making vaccines against new viruses. This “platform” uses messenger RNA (mRNA) as the delivery agent to teach the body how to recognize and fight a new virus.


The first vaccines to reach the market use this “platform” strategy. The other vaccines that are still being studied are based on vaccine strategies that have been used in the past, but these take longer. Part of the delay in studying a new vaccine is the time it takes to design a high quality and safe clinical trial. For COVID-19, international organizations came together to agree on a study outline and goals.


Another big difference is that governments agreed to pay companies to produce large amounts of their vaccines in advance, even while trials were testing how well the vaccine actually worked in people. If those clinical trials showed a vaccine didn’t work, or had unacceptable side effects, it would be thrown out – but the company wouldn’t lose money. On the other hand, if the trials showed a vaccine worked and was safe, the companies would be ready to ship it out – which is what’s happening now.


Another source of speed: The fact that the pandemic was so out of control in the U.S. and other countries this summer and fall, when the clinical trials were going on. Because the people who volunteered to get the vaccine had a high chance of being exposed to the virus in their everyday lives, researchers could see within months how many of the ones who got actual vaccines got sick with COVID-19, compared with the people in the groups that got the placebos.


The approval process through the FDA had an independent panel of experts look at the data from the studies, and ask tough questions of the vaccine makers before voting to approve it on an emergency basis. The FDA is also requiring the companies to track what happens to people who took part in its studies, and the CDC will monitor what happens to people who get the vaccine outside the studies.



FACT: The mRNA-based vaccines do not change a person’s DNA


Myths and fears: Because the mRNA approach to vaccines is new, you might have seen claims and worries about what might happen after it’s injected into the body. These include the claim that the genetic material in the vaccine will find its way into your DNA permanently.

The bottom line: The first two COVID-19 vaccines contain a specific kind of genetic material called mRNA. The mRNA in the vaccines doesn’t need to go into the nucleus of a cell, where DNA is stored, in order to accomplish its mission of teaching the immune system how to recognize coronavirus.


In order to become part of your DNA, the mRNA would have to go through an extremely unlikely, though hypothetically possible, process to be converted from mRNA to DNA, reach the nucleus of the cell, and get “stitched” into your DNA. Even if this did happen, it’s extremely unlikely to cause problems.


More detail: The “m” in mRNA stands for “messenger”, and that’s a good description of what the vaccine does. It brings a message into the body, to tell the immune system what to look for if coronavirus gets in.


The mRNA gets decoded by structures in cells called ribosomes, but this happens outside the nucleus where the DNA is stored. The decoded message then tells the cells of the immune system what some of the proteins on the outside of the coronavirus looks like. This helps them get ready to attack coronavirus in the future if you get exposed to it.


The human body can convert DNA into mRNA – in fact, our bodies wouldn’t work if this didn’t happen. But this is typically a one-way process. Theoretically, there is a way for your body to convert mRNA into DNA, but only if your cells manage to hijack proteins encoded by a naturally occurring “jumping gene” called a LINE-1 retrotransposon. This gene tells the cell how to make a protein called reverse transcriptase, which can “read” mRNA and churn out a stretch of DNA. But the chances of this happening are extremely small. And even if it does, and the new DNA gets integrated into your existing DNA, the chances that this would cause negative consequences are even smaller.


The benefit of receiving the vaccine, and having a greatly reduced chance of developing serious COVID-19, far outweighs the remote chance of such an event.


Some of the claims about mRNA might come from confusion about what we do know about viruses in our body. Some viruses, like the virus that causes chicken pox, can sleep in our cells for decades, only to wake up later and cause shingles. Other viruses, like HIV, bring their own copy of reverse transcriptase into your cells, which allows them to convert their RNA into DNA and then make themselves part of our DNA. But none of the COVID-19 vaccines available now or now being tested contain an intact coronavirus -- just enough mRNA, protein or RNA to alert the immune system.

FACT: COVID-19 vaccines can cause a short fever, headache, fatigue, sore arm or chills, especially after the second dose. Other reactions are extremely rare.

Myths and fears: Some people have seen claims that large numbers of people are getting seriously ill from the vaccine, that the risks of the vaccine aren’t being reported, or that officials know there are long-term risks but are keeping them secret.


Just as with other vaccines, the COVID-19 vaccines can cause temporary effects soon after they enter the body and start teaching the immune system to go after the coronavirus. The most common reactions are headaches, arm pain, body aches, chills or fever lasting a few hours to a few days. Taking an over-the-counter painkiller can help ease these.


Health authorities have also reported a few cases of severe allergic reactions or a face-nerve condition called Bell’s palsy among the millions of people vaccinated so far. These were extremely rare, but they have received a lot of attention.


Why these temporary effects happen: Vaccines work by getting the immune system to fight. So it is common for highly effective vaccines, like the tetanus shot, to give people some symptoms. This is a sign the vaccine is doing what it was meant to do: Wake up the immune system and prepare it to fight off an infection in the future. The COVID-19 vaccines tend to cause these same sorts of symptoms: Soreness in the muscle where the shot went in, some fatigue, and perhaps feverish. All of these symptoms are good news because they indicate the vaccine is working. And all can be made better with common over-the-counter painkillers like acetaminophen (Tylenol) or ibuprofen (Advil or Motrin.)


Coincidental infections: The COVID-19 vaccines don’t contain coronavirus, so the vaccinated person can’t get COVID-19 from the vaccine. But they or someone they live with might get sick from a virus or bacteria that they picked up around the time they got vaccinated.


Coronavirus is widespread right now, so a vaccinated person may have been exposed to it in the days before they got vaccinated. If post-vaccination symptoms last more than a day or two, or if they include a cough, shortness of breath, diarrhea, or loss of taste or smell, the vaccinated person should talk to their health provider and stay home in isolation (away from others) until they can get tested for the coronavirus.


We also don’t know yet if a person who got the vaccine can still spread coronavirus if they come in contact with it. That’s why vaccinated people still need to wear masks until researchers can study this more. The flu and common cold viruses are also circulating now, so a person could have been exposed to these before they were vaccinated, and get symptoms from one of those viruses. If so, they should stay home, get rest, drink fluids and take basic painkillers to ease their symptoms. They should seek medical attention for high fever or prolonged symptoms.


Rare but more serious issues: There have been several cases of anaphylaxis, or severe allergic reaction, among people with a history of such reactions who received the COVID-19 vaccine.


Anyone who carries an Epi-Pen or has experienced an allergic reaction so serious that it made them unconscious or faint should mention this when they receive the vaccine. Right now, people who have had a serious allergic reaction (like anaphylaxis) to anything are being asked to stay in the vaccination location for about a half an hour after receiving the vaccine, with someone trained to care for serious allergic reactions watching them.

The reports of Bell’s palsy (which affects the nerves of the face and is not the same as cerebral palsy) are being investigated. But the number of cases among vaccinated people was about what might occur naturally in the general population.


Long-term problems: No one has had the vaccine in their body for more than nine months (as of late January 2020), so the honest answer is we don’t know yet if these vaccines cause long-term problems. Only time and accurate tracking will tell for sure; scientists have to look for unusual patterns of disease in groups of vaccinated people.

That’s why everyone who gets vaccinated is being encouraged to track and report any symptoms they may feel in the short and long term, and to tell their health provider.

Health officials are already watching out for any patterns of problems that are out of the ordinary. So far, they have not seen any. But the scrutiny on these vaccines, and the fact that there are many more varieties of the COVID-19 vaccine now being tested, mean that we would have an early warning and alternatives.


Meanwhile, the threat of COVID-19 is very real right now. It is killing thousands of Americans every day, and leaving many others with lasting symptoms and disability from the disease.

FACT: The COVID-19 vaccines do not contain a live or whole coronavirus, microchips, tracer technology, fetal tissue, stem cells, mercury, aluminum etc.

Myth and fears: All of these things, and more, have been mentioned in claims that we’ve seen on the internet, or heard about from people who contacted us. People who hear these claims may be worried about health effects, being tracked wherever they go, or even faith-related problems.


The bottom line: The first two vaccines to reach the market contain only snippets of genetic material, salt, sugar and fat. The other vaccines being developed will contain weakened or inactive forms of “common cold” viruses, and substances commonly found in many vaccines.


What about metals? The most common uses of metals in vaccines are in substances called preservatives and adjuvants. The first two COVID-19 vaccines don’t have preservatives, which is why they must stay frozen until they are thawed for injection. They also don’t contain additives called